Evolution by innovation as a driving force to improve TCR-T therapies
Adoptive cell therapies continually evolve through science-based innovation. Specialized innovations for TCR-T therapies are described here that are embedded in an End-to-End Platform for TCR-T Therapy Development which aims to provide solutions for key unmet patient needs by addressing challenges o...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1216829/full |
| _version_ | 1797677975096786944 |
|---|---|
| author | Dolores J. Schendel Dolores J. Schendel |
| author_facet | Dolores J. Schendel Dolores J. Schendel |
| author_sort | Dolores J. Schendel |
| collection | DOAJ |
| description | Adoptive cell therapies continually evolve through science-based innovation. Specialized innovations for TCR-T therapies are described here that are embedded in an End-to-End Platform for TCR-T Therapy Development which aims to provide solutions for key unmet patient needs by addressing challenges of TCR-T therapy, including selection of target antigens and suitable T cell receptors, generation of TCR-T therapies that provide long term, durable efficacy and safety and development of efficient and scalable production of patient-specific (personalized) TCR-T therapy for solid tumors. Multiple, combinable, innovative technologies are used in a systematic and sequential manner in the development of TCR-T therapies. One group of technologies encompasses product enhancements that enable TCR-T therapies to be safer, more specific and more effective. The second group of technologies addresses development optimization that supports discovery and development processes for TCR-T therapies to be performed more quickly, with higher quality and greater efficiency. Each module incorporates innovations layered onto basic technologies common to the field of immunology. An active approach of “evolution by innovation” supports the overall goal to develop best-in-class TCR-T therapies for treatment of patients with solid cancer. |
| first_indexed | 2024-03-11T22:51:54Z |
| format | Article |
| id | doaj.art-a0504e06970a49f19961749cbec0667e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T22:51:54Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a0504e06970a49f19961749cbec0667e2023-09-21T22:25:52ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.12168291216829Evolution by innovation as a driving force to improve TCR-T therapiesDolores J. Schendel0Dolores J. Schendel1Medigene Immunotherapies GmbH, Planegg, GermanyMedigene AG, Planegg, GermanyAdoptive cell therapies continually evolve through science-based innovation. Specialized innovations for TCR-T therapies are described here that are embedded in an End-to-End Platform for TCR-T Therapy Development which aims to provide solutions for key unmet patient needs by addressing challenges of TCR-T therapy, including selection of target antigens and suitable T cell receptors, generation of TCR-T therapies that provide long term, durable efficacy and safety and development of efficient and scalable production of patient-specific (personalized) TCR-T therapy for solid tumors. Multiple, combinable, innovative technologies are used in a systematic and sequential manner in the development of TCR-T therapies. One group of technologies encompasses product enhancements that enable TCR-T therapies to be safer, more specific and more effective. The second group of technologies addresses development optimization that supports discovery and development processes for TCR-T therapies to be performed more quickly, with higher quality and greater efficiency. Each module incorporates innovations layered onto basic technologies common to the field of immunology. An active approach of “evolution by innovation” supports the overall goal to develop best-in-class TCR-T therapies for treatment of patients with solid cancer.https://www.frontiersin.org/articles/10.3389/fonc.2023.1216829/fulladoptive cell therapyCD40/CD40L interactionsPD-1/PD-L1 inhibitionTCR-T therapyswitch receptors |
| spellingShingle | Dolores J. Schendel Dolores J. Schendel Evolution by innovation as a driving force to improve TCR-T therapies Frontiers in Oncology adoptive cell therapy CD40/CD40L interactions PD-1/PD-L1 inhibition TCR-T therapy switch receptors |
| title | Evolution by innovation as a driving force to improve TCR-T therapies |
| title_full | Evolution by innovation as a driving force to improve TCR-T therapies |
| title_fullStr | Evolution by innovation as a driving force to improve TCR-T therapies |
| title_full_unstemmed | Evolution by innovation as a driving force to improve TCR-T therapies |
| title_short | Evolution by innovation as a driving force to improve TCR-T therapies |
| title_sort | evolution by innovation as a driving force to improve tcr t therapies |
| topic | adoptive cell therapy CD40/CD40L interactions PD-1/PD-L1 inhibition TCR-T therapy switch receptors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1216829/full |
| work_keys_str_mv | AT doloresjschendel evolutionbyinnovationasadrivingforcetoimprovetcrttherapies AT doloresjschendel evolutionbyinnovationasadrivingforcetoimprovetcrttherapies |